Fu Li

Vice PresidentĀ and Head of Biology

Fu Li is the Head of Biology at Pheon Therapeutics. Prior to joining Pheon, Fu was the Director of Biology at Mersana Therapeutics, where he led a team to expand the pipeline of cytotoxic ADCs. Prior to that, Fu has led translational research at Agio Pharmaceuticals, and discovery work and Seagen. Fu has contributed to multiple clinical stage programs and published multiple manuscripts on the modes of action for ADC drugs, including brentuximab vedotin.

Fu has earned a PhD in molecular genetics from the Ohio State University, working the role of tumor microenvironment. He also trained as a Presidential Postdoctoral Fellow at the Oncology group at the Novartis Institutes for Biomedical Research.